Search alternatives:
teer decrease » greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 11,181 - 11,200 results of 15,595 for search '(( 50 ((teer decrease) OR (mean decrease)) ) OR ( 59 ((nn decrease) OR (a decrease)) ))', query time: 0.67s Refine Results
  1. 11181
    Table_8_The Immune Atlas of Human Deciduas With Unexplained Recurrent Pregnancy Loss.xlsx

    Table_8_The Immune Atlas of Human Deciduas With Unexplained Recurrent Pregnancy Loss.xlsx by Pengfei Chen (462170)

    Published 2021
    “…Especially, we identified a subpopulation of CSF1+ CD59+ KIRs-expressing dNK cells in normal deciduas, while the proportion of this subpopulation was decreased in URPL deciduas. …”
    Save to List
    Saved in:
  2. 11182
    Image_2_The Immune Atlas of Human Deciduas With Unexplained Recurrent Pregnancy Loss.jpeg

    Image_2_The Immune Atlas of Human Deciduas With Unexplained Recurrent Pregnancy Loss.jpeg by Pengfei Chen (462170)

    Published 2021
    “…Especially, we identified a subpopulation of CSF1+ CD59+ KIRs-expressing dNK cells in normal deciduas, while the proportion of this subpopulation was decreased in URPL deciduas. …”
    Save to List
    Saved in:
  3. 11183
    Table_7_The Immune Atlas of Human Deciduas With Unexplained Recurrent Pregnancy Loss.xlsx

    Table_7_The Immune Atlas of Human Deciduas With Unexplained Recurrent Pregnancy Loss.xlsx by Pengfei Chen (462170)

    Published 2021
    “…Especially, we identified a subpopulation of CSF1+ CD59+ KIRs-expressing dNK cells in normal deciduas, while the proportion of this subpopulation was decreased in URPL deciduas. …”
    Save to List
    Saved in:
  4. 11184
    Junctional buckling model.

    Junctional buckling model. by Annafrancesca Rigato (698112)

    Published 2024
    Save to List
    Saved in:
  5. 11185
    Descriptive statistics for variables.

    Descriptive statistics for variables. by Lingshu Zhang (10753938)

    Published 2024
    Save to List
    Saved in:
  6. 11186
    Three-stage DEA model.

    Three-stage DEA model. by Lingshu Zhang (10753938)

    Published 2024
    Save to List
    Saved in:
  7. 11187
    SFA regression results.

    SFA regression results. by Lingshu Zhang (10753938)

    Published 2024
    Save to List
    Saved in:
  8. 11188
    Gene ontology (GO) slim term enrichment of the core set genes for biological processes.

    Gene ontology (GO) slim term enrichment of the core set genes for biological processes. by Alex Yi-Lin Tsai (3808654)

    Published 2017
    Save to List
    Saved in:
  9. 11189
    Indirect BIS recording via the interface device (clinical study 1).

    Indirect BIS recording via the interface device (clinical study 1). by Hideki Harada (2159767)

    Published 2021
    Save to List
    Saved in:
  10. 11190
    E2 and VENUS are equally detectable in CHIKV-infected EVA cells at 24 hpi.

    E2 and VENUS are equally detectable in CHIKV-infected EVA cells at 24 hpi. by Brian C. Ware (8544672)

    Published 2024
    Save to List
    Saved in:
  11. 11191
    Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:
  12. 11192
    DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:
  13. 11193
    Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:
  14. 11194
    Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:
  15. 11195
    DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:
  16. 11196
    Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:
  17. 11197
    Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:
  18. 11198
    DataSheet_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    DataSheet_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:
  19. 11199
    Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:
  20. 11200
    DataSheet_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

    DataSheet_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
    Save to List
    Saved in:

Search Tools: